Conduct BE study or present safety data: CDSCO Panel tells IQVIA on anti-cancer Drug Daratumumab study
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined IQVIA to conduct the bioequivalence study or present safety data for the anti-cancer monoclonal antibody medication, Daratumumab.
This came after IQVIA presented phase 1/3 clinical study protocol no.: CT-P44 3.1 version no. 1.0 dated 21-OCT-2024.
Daratumumab is a monoclonal antibody that treats multiple myeloma (MM) by binding to the CD38 protein on MM cells. This binding triggers a series of events that lead to the death of MM cells. Daratumumab binds to CD38, causing cells to apoptose via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis.
Daratumumab binds to CD38, a protein that's overexpressed on MM cells. This binding activates the immune system to recognize the MM cells. The immune system then attacks and kills the MM cells.
At the recent SEC meeting for Oncology held on February 20, 2025, the expert panel reviewed the phase 1/3 clinical study protocol no.: CT-P44 3.1 version no. 1.0 dated 21-OCT-2024.
After detailed deliberation, the committee opined that the firm should conduct a bioequivalence study or present safety data for further review by the committee.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.